The Biden administration has put forward a proposal to expand Medicare and Medicaid coverage, allowing up to 7.4 million Americans access to costly weight-loss drugs such as Ozempic and Wegovy. Under this initiative, millions of obese Americans could benefit from increased support for anti-obesity medications, which are primarily GLP-1 drugs. The proposal aims to address the growing demand for these medications while alleviating healthcare costs for employers. The White House believes that the expansion of coverage through government-funded insurance may offer a more feasible solution compared to private plans. This move is anticipated to generate significant interest in the health sector and boost the stock prices of weight-loss drug manufacturers.